GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Interest Income

Sinovac Biotech (Sinovac Biotech) Interest Income : $136.4 Mil (TTM As of Jun. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Sinovac Biotech's interest income for the six months ended in Jun. 2023 was $29.6 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2023 was $136.4 Mil.


Sinovac Biotech Interest Income Historical Data

The historical data trend for Sinovac Biotech's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Interest Income Chart

Sinovac Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.02 2.00 1.93 102.57 190.82

Sinovac Biotech Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.80 71.76 84.00 106.82 29.59

Sinovac Biotech Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $136.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinovac Biotech (Sinovac Biotech) Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6

Sinovac Biotech (Sinovac Biotech) Headlines

From GuruFocus

SINOVAC to Showcase Products at CPHI Frankfurt

By Business Wire Business Wire 10-28-2022

SINOVAC Varicella Vaccine Prequalified by WHO

By Business Wire Business Wire 11-04-2022